IgniteIt · Cannabis Capital ConferenceMIAMI 2027March 24–26 · The Diplomat Beach Resort, Hollywood FL
The story behind the story.
How Much Does It Cost to Wait?
Cannabis has spent years waiting.
For Schedule III. For better access to capital. For uplisting. For new state markets. For buyers to improve their offers.
But waiting isn’t financially neutral.
Some companies can collect cash while they wait. Others pay interest, issue shares, carry vacant properties, or make investment decisions around regulatory changes whose timing they don’t control.
This week, we’re asking a simple question:
Who can afford to wait — and what does waiting cost everyone else?
And if you’re in Los Angeles, we can continue that conversation in person. IgniteIt’s California Market Spotlight is Oct. 7, bringing operators, investors, and decision-makers together at Hotel Indigo in Downtown LA.
— Nico Rodriguez, Managing Editor
Oct. 7 in Los Angeles California Market Spotlight, Hotel Indigo, Downtown LA — join us
One Date
Oct. 13
That’s when the government must respond to the latest pause in the federal marijuana rescheduling proceeding. It is not a decision date.
DEA Chief Administrative Law Judge Derek C. Julius stayed the case on Sept. 29 while considering whether to admit a new GAO report and allow additional briefing. Cannabis analyst Pablo Zuanic argues the delay could push completion of broader rescheduling into the third quarter of 2027.
For operators, a catalyst can still be valuable without being close. But the longer it takes, the more important the balance sheet becomes.
The Big Story
Who Can Afford to Wait?
Anthony Coniglio has a phrase for the investment case around NewLake Capital Partners:
“Get paid to wait.”
In the first half of 2026, NewLake collected 100% of contractual rent. It maintained its $0.43 quarterly dividend, and its CEO said the payout ratio was 88%. The REIT also extended its $90 million credit facility to May 2029 while reducing its borrowing spread.
Coniglio isn’t building the company’s underwriting around Schedule III. His point? The reform doesn’t turn a weak operator into a strong tenant overnight.
Tax relief could improve cash flow, while better access to equity could allow operators to reduce debt and refinance. Furthermore, uplisting could broaden the investor base, but NewLake still wants to know whether an operator can run stores and cultivation facilities profitably.
“How are they performing on an operating cash flow basis? How are they growing their business?”
Anthony Coniglio · CEO, NewLake Capital Partners
Hope isn’t a strategy
NewLake extended its credit facility early.
“You take capital when it’s available,” Coniglio told IgniteIt. “Hope isn’t a strategy.”
That’s how you get paid to wait: have enough financial room that the catalyst doesn’t need to arrive on schedule.
Read our full interview with Anthony ConiglioAre you in the C-suite?
We want to know how you’re thinking about the market.
If you’re a CEO, CFO, or senior executive in cannabis, tell us what you’re seeing inside your business — capital allocation, margins, expansion, regulation, operating costs, or the decisions keeping you up at night.
Email the desk. You could be featured in a future issue of IgniteIt Intelligence.
The Other Side of Waiting
When Time Turns Into Dilution
Vireo Growth gives us a different version of the same problem: the company signed an agreement to acquire an $18.1 million promissory note using shares.
Battle Green can trigger the purchase at a $19.50 share issuance price; Vireo can trigger it at $18.60. But if neither side acts before the note matures, Vireo must acquire it using shares priced at its trailing 30-day VWAP, subject to exchange minimums.
If the stock is lower at maturity, more shares are required to cover the same principal. The deal preserves cash. But cash preservation and value preservation aren’t necessarily the same thing.
As our Chief Economic Columnist Rolando García argued in his recent analysis of cannabis expansion, the number shareholders should watch isn’t simply post-deal revenue.
It’s the per-share arithmetic.
NewLake takes capital before it needs it. Vireo’s agreement gives it flexibility today while leaving part of tomorrow’s share count dependent on the market.
The SpreadWeek 4 of 11
Curaleaf / Aurora: The Price Moved
We started tracking this transaction because the market was telling us something.
Curaleaf’s original offer valued Aurora at $4 per share, while Aurora’s stock traded below the implied consideration. Rolando García argued that the spread reflected doubt about whether the deal would actually close, rather than free money sitting on the table.
Now the bidder has moved.
Curaleaf raised its offer from $4 to $5 per Aurora share — a 25% increase. Aurora holders would get 0.4013 Curaleaf shares plus US$1 in cash, and the deadline moves from Dec. 1 to Dec. 4.
That changes the arithmetic, but it also validates why we’ve been following the spread rather than simply the headline offer price.
Aurora told shareholders $4 wasn’t enough. Curaleaf spent weeks arguing that it was. Now Curaleaf is offering $5.
Curaleaf / AuroraAs of Oct. 6 close
8.4%Aurora’s discount
to offer value
to offer value
Aurora closed at $4.59 against revised consideration worth $5.01. Last week, under the $4 terms, the gap was 10.1%.
57%Annualized return
if it closes
if it closes
$1.00Cash per share,
up from $0.75
up from $0.75
58Days until
Dec. 4 expiry
Dec. 4 expiry
Why it matters: Aurora is up 17% since Friday’s $3.92 close, and it didn’t just catch up to the new offer — the gap narrowed, from 10.1% a week ago to 8.4%. The market is pricing a better bid and slightly more confidence that a deal gets done. It still isn’t pricing certainty.
But is $5 enough to get the shares Curaleaf needs?
DW Analysis
What If Schedule III Arrives Before the Rules Fit Together?
Schedule III is usually modeled as a tax catalyst.
But Dickinson Wright’s analysis raises a harder operational question: what happens if federal tax treatment changes before state cannabis systems can cleanly separate the businesses that qualify?
Consider Maryland.
Medical and adult-use inventory isn’t universally separated before sale. In some cases, medical status is effectively determined at the transaction level when the patient’s eligibility and purchase allowance are verified. That creates unresolved questions about how a dual-use operator would allocate labor, rent, utilities, and inventory costs between federally recognized medical activity and adult-use operations.
Michigan creates a different problem: inventory can move between co-located medical and adult-use licenses, creating a point at which the same product’s federal characterization becomes uncertain.
The business implication is straightforward.
Removing 280E from a spreadsheet is easy. Implementing two regulatory systems inside the same operation may not be.
For investors trying to estimate the value of Schedule III, the eventual tax benefit therefore isn’t the only variable worth modeling.
Implementation has a cost, too.
Analysis based on work by Dickinson Wright attorneys Ben Sobczak, Jon Wachs and Chris Lynch.
Partner InsightSponsored
From our partner, Azuca
Nano Isn’t the Only Way to Make an Edible Fast
Fast-acting edibles are often sold on particle size. Azuca wants manufacturers to ask a broader question: How does the infusion perform once it becomes an actual gummy?
Its Science of Fast-Acting research follows that question from pharmacokinetics through consumer preference. In a peer-reviewed study, TiME INFUSION® reached peak blood THC at 30 minutes versus 60 minutes for a traditional edible.
Then comes the finished product. In a blind comparison using the same flavor and dose, 86% rated the TiME INFUSION® gummy’s taste good or very good, versus 60% for a leading nano-emulsion gummy. Azuca also reports higher scores across texture, overall liking, effects, and purchase intent.
The paper sums up the argument in one line: “‘Nano’ describes a particle. It doesn’t describe an experience.”
Read our analysis of the science →
Sponsored content produced in partnership with Azuca.
Signal
RAW Wants Competitors to Copy It
Most brands don’t enter a market by telling competitors how to reproduce what they’re doing.
RAW founder Josh Kesselman is taking a different approach.
RAW Genetics has launched seven flower, rosin, and infused formats across five states, and Kesselman says the company plans to publish its pre-roll construction methods and encourage other manufacturers to improve on them.
The strategy is worth watching because RAW is entering one of cannabis’s most familiar product formats and arguing that raising the category’s quality floor can strengthen the brand rather than weaken its differentiation.
Or, in Kesselman’s words, give the industry “something worth copying.”
The Bottom Line
Time belongs on the balance sheet.
NewLake can collect rent and pay a dividend amid uncertain catalysts; Vireo preserves cash today at the potential cost of future dilution.
And Aurora waited rather than accept $4. Curaleaf just came back with $5.
The next time someone tells you a cannabis catalyst is coming, don’t stop at asking when. Ask:
What happens to the capital while we wait?
October 7 · Los Angeles
Oct. 7: IgniteIt California
This week’s newsletter has been about decisions made while the industry waits.
On Oct. 7, we put the people making those decisions in the same room.
IgniteIt’s California Market Spotlight is Oct. 7 at Hotel Indigo in Downtown Los Angeles, bringing together operators, investors, and industry leaders to talk about what comes next for the world’s largest legal cannabis market.
Capital is moving. M&A is evolving. Margins remain under pressure. Federal reform is still uncertain. Come ask the people allocating the capital, running the businesses, and making the deals.
Register for IgniteIt CaliforniaUpcoming IgniteIt Events
IgniteIt California Market SpotlightOct 7 · Los Angeles
Cannabis Capital & Policy SummitNov 18 · Washington, D.C.